Assessment of temporary warfarin reversal in patients with left ventricular assist devices: the KVAD study

Due to advances in technology and limited availability of donor hearts, thousands of patients with advanced heart failure are supported with left ventricular assist devices (LVAD) either as a bridge-to-transplant, bridge-to-candidacy, or as destination therapy for those ineligible for a heart transplant.1 –3 The survival profile continues to improve, with 1 and 5 year survival rates of 83% and 52% respectively, allowing patients supported on these devices to live for longer periods of time.3–5

Source: Journal of Cardiac Failure - March 21, 2024 Category: Cardiology Authors: Katelyn W. Sylvester, Jessica Grandoni, Megan Rhoten, Lara Coakley, Erin Matiello-Lyons, Katie Frankel, Brooke Fortin, Kate Jolley, Hae Soo Park, Revital Freedman, Mandeep R. Mehra, Michael M. Givertz, Jean M. Connors Source Type: research